Bain Capital’s deal to buy the memory chip business of Toshiba for some US$18 billion might not close after all. The Wall Street Journal reported that Toshiba has “mostly given up” on the agreement because the Japanese conglomerate’s leadership doesn’t think antitrust approval from the Chinese government is likely to occur soon.
Toshiba has now reportedly begun weighing whether to take its NAND memory unit public, find a different buyer or hold on to the business after the parties failed to close the deal by an April 1 deadline they reported.
A consortium including Bain Capital, Dell, Apple and South Korean chipmaker SK Hynix initially agreed to buy the division, which provides tech for smartphones and other electronic devices, for some US$18 billion this past September, with Toshiba committing to re-invest as part of the transaction. A group that included KKR was also in the mix to acquire the unit last year until the Bain consortium won out.
Toshiba had sought to sell the chip unit after sustaining crippling losses from its bankrupt US nuclear power plant company, Westinghouse Electric. But in January, a division of Brookfield Asset Management agreed to buy Westinghouse for US$4.6 billion, with a reported US$3.7 billion added to Toshiba’s capital base. And late last year, the company raised some US$5 billion in new capital.
Toshiba still faces a legal challenge from chipmaker Western Digital, a Toshiba partner that objected to the deal. But those two businesses reached a truce and an eventual close looked likely until March, when talk of a possible trade war between the US and China began to take shape.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas